Table of Contents
Understanding Bispecific Antibodies
Bispecific Antibodies or CAR T-cell Therapy?
Eligibility and Administration
Do I Need A Caregiver to Receive Bispecifics?
Side Effects of Bispecific Antibodies
Cytokine Release Syndrome (1/4)
Cytokine Release Syndrome (2/4)
Cytokine Release Syndrome (3/4)
Cytokine Release Syndrome (4/4)
Teclistamab Side Effect Profile
Elranatamab Side Effect Profile
Talquetamab Side Effect Profile
Side Effect Management and Support
Keep Your Healthcare Team Informed
FDA Approved Bispecific Antibodies
Bispecific Antibodies in Clinical Trials
Bispecific Antibodies Clinical Trials
Treatment Strategies with Bispecific Antibodies
Immunotherapy Treatment Sequencing (1/3)
Immunotherapy Treatment Sequencing (2/3)
Immunotherapy Treatment Sequencing (3/3)
Bispecifics for Newly Diagnosed Myeloma
Bispecifics in High-Risk Myeloma
Relapse on Bispecific Antibody Therapy
Refractory to Bispecific Antibody Therapy
Caregiver Role in Bispecific Antibody Therapy
Financial Resources for Bispecific Antibody Therapy
Pharmaceutical Support Resources
HealthTree Financial Resources
Future Considerations of Bispecific Antibody Therapy
Questions to Ask Your Doctor about Bispecific Antibody Therapy